Navigation Links
MSU launches groundbreaking drug trial in Africa

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

It will be the first test of the anti-seizure medication levetiracetam, or LVT, for controlling seizures caused by cerebral malaria, a severe form of the disease that affects brain function in some three million children, mostly in sub-Saharan Africa.

About one in 10 children who survive cerebral malaria are left with epileptic seizures, said the trial's lead researcher Gretchen Birbeck, a professor of neurology and ophthalmology in the College of Osteopathic Medicine.

"This trial is aimed at improving seizure control with the hope of finding a path toward epilepsy prevention," Birbeck said. "Since oral LVT is relatively affordable for short-term use and feasibly could be delivered in resource-limited settings, this therapy could potentially be scaled up for broad use throughout malaria endemic African countries."

The trial will include about 40 children in Malawi. If all safety standards are met, dosage will be increased until 75 percent of the children are free of seizures for 24 hours.

A wireless EEG monitoring device the size of a deck of cards will tell the researchers if LVT is keeping the children seizure-free. Developed by New York-based biotechnology firm BioSignal Group, the device can be worn on the child's arm and transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"Unfortunately, many children with cerebral malaria continue to have seizures with no clinical evidence that seizures are occurring, but their brains still are being affected," said Birbeck, who also is director of MSU's International Neurologic and Psychiatric Epidemiology Program. "To evaluate the effectiveness of LVT, we need continuous EEG monitoring, which is very tough to do even in the best environment."

If the study finds a safe and effective dosage of LVT for cerebral malaria seizures, the team will scale it up and put the drug to the test in a randomized trial without the specialized technology.

The trial, part of MSU's Blantyre Malaria Project at Queen Elizabeth Central Hospital, is being funded with a nearly $2 million grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke.

It's part of a broader effort by Birbeck to, as she says, "bring epilepsy out of the shadows." The disease keeps many of its victims from holding a job or going to school, and the stigma associated with seizures prevent many of them from getting the treatment they need.

Birbeck is working in Malawi and Zambia to educate people about the disease so they aren't afraid to seek treatment. With her help, more and more patients are getting help and living productive lives.

Her ultimate goal is to find a way to keep people from getting epilepsy in the first place.

"The best legacy would be when they didn't need epilepsy treatment," she said. "That would be the nicest of all."


Contact: Andy McGlashen
Michigan State University

Related biology news :

1. NTU launches new centre to develop new eye-deas for occular therapeutics
2. Elsevier launches new open access journal: Molecular Metabolism
3. Canada launches first gene therapy trial for Fabry disease
4. Elsevier launches new journal: Journal of Unconventional Oil and Gas Resources
5. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
6. Wake Forest Baptist Medical Center Launches Wake Forest Innovations
7. Neurotechnology Launches SkyBiometry Spin-off Company to Deliver SaaS Biometric Identification and Feature Analysis
8. Elsevier launches new open access journal -- Case Studies in Engineering Failure Analysis
9. Gene sequencing project identifies abnormal gene that launches rare childhood leukemia
10. Smithsonian launches global marine biodiversity project with $10 million donation
11. Rice launches sweeping Energy and Environment Initiative
Post Your Comments:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
Breaking Biology Technology: